BioSpace News Archive

Whether the problem is the actual work itself, your co-workers, or the overall company atmosphere, you need to proactively take action if your new job not working out.

Results from multiple Phase III trials show consistent improvements in pain relief and physical function.

10X Genomics just agreed to acquire ReadCoor, Inc., an innovator in the nascent field of in situ technology. The $350 million deal comes on the heels of 10x Genomics’ August acquisition of CartaNA AB, a Stockholm-based developer of in situ RNA analysis technology.

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline Phase 1 clinical trial results of OTX-CSI

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and oral presentation details of two sets of data at the virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting. The oral presentations will take place during the “Research Pipeline: New Findings on Diagnost

Research Solutions/Reprints Desk (NASDAQ: RSSS), a pioneer in providing cloud-based workflow solutions for R&D driven organizations, today announced that it has partnered with BIO Business Solutions to help life sciences companies save time and money on scholarly literature access via its award-winning Article Galaxy research platform

Datavant, the leader in helping life sciences and healthcare organizations safely connect their data while protecting patient privacy, today announced $40 million in Series B funding, bringing Datavant’s cumulative fundraising to $83 million.

Certara Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

- Recombinetics Inc., a leading gene editing company with platform technology in therapeutics development, today announced that it has merged its efforts with Makana Therapeutics, a leader in the field of xenotransplantation.

US Patent No. 10,424,399 has been granted to Integrated Chemistry Design, Inc. (ICD) headquartered in Oceanside, CA.